Health economics and outcomes research: informing companion diagnostic development, guidelines, adoption and reimbursement.

Charlotte Schubert, Cancer drugs find a companion with new diagnostic tests. Nature Medicine. ,vol. 17, pp. 1157- 1157 ,(2011) , 10.1038/NM1011-1157

Jakub Adamski, Brian Godman, Gabriella Ofierska-Sujkowska, Bogusława Osińska, Harald Herholz, Kamila Wendykowska, Ott Laius, Saira Jan, Catherine Sermet, Corrine Zara, Marija Kalaba, Roland Gustafsson, Kristina Garuolienè, Alan Haycox, Silvio Garattini, Lars L Gustafsson, Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research. ,vol. 10, pp. 153- 153 ,(2010) , 10.1186/1472-6963-10-153

Charles Schmidt, Larger companies dominate cancer companion diagnostic approvals. Nature Biotechnology. ,vol. 29, pp. 955- 956 ,(2011) , 10.1038/NBT1111-955

Jim Lee, Erik Tollefson, Matthew Daly, Edward Kielb, A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 13, pp. 361- 370 ,(2013) , 10.1586/ERP.13.23

Eric A. Collisson, Raymond J. Cho, Joe W. Gray, What are we learning from the cancer genome Nature Reviews Clinical Oncology. ,vol. 9, pp. 621- 630 ,(2012) , 10.1038/NRCLINONC.2012.159

Carlos L. Arteaga, José Baselga, Impact of genomics on personalized cancer medicine. Clinical Cancer Research. ,vol. 18, pp. 612- 618 ,(2012) , 10.1158/1078-0432.CCR-11-2019